Pfizer Inc. (NYSE: PFE) has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. For the fourth consecutive year, CDP named Pfizer to its Carbon Disclosure Leadership Index, which highlights the company's climate change disclosure practices.

More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

New Patient Reported Outcomes (PRO) data presented today at the European Association for the Study of Diabetes (EASD) congress in Stockholm, challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies.(1)

Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer.

What makes Merck what it is, what distinguishes it from other companies? Answers to these questions can now be found in an image brochure entitled "The Merck Way". Dr. Walter Huber, Head of Corporate Communications, explained: "The 28-page illustrated brochure presents the company's culture, values, history, strategy and objectives as well as the business sectors and the ownership structure.

Following the 1st July announcement by GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced plans to refocus the development programme of ofatumumab in autoimmune indications.